diabetes
Conditions
Interventions
Group 1:Treatment with liraglutide
Group 2:placebo
Group 3:Human umbilical cord mesenchymal stem cells
Group 4:liraglutide+HUCMs
Sponsors
The 900th Hospital of the Joint Logistics Team
Eligibility
Sex/Gender
All
Age
30 Years to 60 Years
Inclusion criteria
Inclusion criteria: 1. All the included patients met the 1999 WHO diagnostic criteria for type 2 diabetes; 2. Aged between 30 and 60; 3. Hemoglobin a1c (HbA1c) 7.5% ~ 10%; 4. Body mass index (BMI) >= 25kg/m2; 5. Previously taking metformin hydrochloride alone >= 1000mg/ day for more than 3 months; 6. The patient met the diagnostic criteria for simple fatty liver disease (NAFL) in China's Guidelines for the Diagnosis and Treatment of Non-alcoholic Fatty Liver Disease (2010 Revision).
Exclusion criteria
Exclusion criteria: 1. Women who are pregnant or planning to be pregnant or breast-feeding; 2. Contraindications for MRI examination (such as metal implants, pacemakers, etc.); 3. Previous history of other liver diseases, such as viral hepatitis, autoimmune hepatitis, liver tumor, etc.; 4. With severe cardiovascular disease, immune system, blood system or endocrine system diseases; 5. Known or likely to be allergic to lyralotide and related products; 6. Thyroid adverse events such as elevated serum calcitonin, goiter, thyroid tumor, or pancreatitis have occurred due to use of other GLP-1 analogues or receptor agonists.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| HbA1c; | — |
Secondary
| Measure | Time frame |
|---|---|
| AST, ALT; | — |
Countries
China
Contacts
Public ContactXiangjin Xu
The 900th Hospital of the Joint Logistics Team
Outcome results
None listed